Medpace Holdings, Inc. Net Change in Cash
Medpace Holdings, Inc. (MEDP) reported Net Change in Cash of $5.64 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-07-23.
Financial Statements › Cash Flow › Change in Cash
us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect · last filed 2026-07-23
- Medpace Holdings, Inc. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), including exchange rate effect for the quarter ending 2026-03-31 was $155.63M.
- Medpace Holdings, Inc. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), including exchange rate effect for the quarter ending 2025-03-31 was -$228.00M, a 241.12% decline year-over-year.
- Medpace Holdings, Inc. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), including exchange rate effect for the quarter ending 2024-03-31 was $161.56M, a 765.95% increase year-over-year.
- Medpace Holdings, Inc. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), including exchange rate effect for the quarter ending 2023-03-31 was $18.66M.
- Medpace Holdings, Inc. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), including exchange rate effect for fiscal 2025 was -$172.39M, a 140.66% decline from fiscal 2024.
- Medpace Holdings, Inc. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), including exchange rate effect for fiscal 2024 was $423.99M, a 95.22% increase from fiscal 2023.
- Medpace Holdings, Inc. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), including exchange rate effect for fiscal 2023 was $217.18M.
- Medpace Holdings, Inc. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), including exchange rate effect for fiscal 2022 was -$433.04M, a 335.94% decline from fiscal 2021.
| Period end | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 3 month | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 6 month | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 9 month | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 12 month |
|---|---|---|---|---|
| 2026-06-30 | $5.64M 10-Q · filed 2026-07-23 | |||
| 2026-03-31 | $155.63M 10-Q · filed 2026-04-23 | |||
| 2025-12-31 | -$172.39M 10-K · filed 2026-02-10 | |||
| 2025-09-30 | -$384.08M 10-Q · filed 2025-10-23 | |||
| 2025-06-30 | -$623.11M 10-Q · filed 2026-07-23 | |||
| 2025-03-31 | -$228.00M 10-Q · filed 2026-04-23 | |||
| 2024-12-31 | $423.99M 10-K · filed 2026-02-10 | |||
| 2024-09-30 | $411.45M 10-Q · filed 2025-10-23 | |||
| 2024-06-30 | $265.44M 10-Q · filed 2025-07-22 | |||
| 2024-03-31 | $161.56M 10-Q · filed 2025-04-22 | |||
| 2023-12-31 | $217.18M 10-K · filed 2026-02-10 | |||
| 2023-09-30 | $66.94M 10-Q · filed 2024-10-22 | |||
| 2023-06-30 | $10.87M 10-Q · filed 2024-07-23 | |||
| 2023-03-31 | $18.66M 10-Q · filed 2024-04-23 | |||
| 2022-12-31 | -$433.04M 10-K · filed 2025-02-11 | |||
| 2022-09-30 | -$430.30M 10-Q · filed 2023-10-24 | |||
| 2022-06-30 | -$418.75M 10-Q · filed 2023-07-25 | |||
| 2022-03-31 | -$378.46M 10-Q · filed 2023-04-25 | |||
| 2021-12-31 | $183.54M 10-K · filed 2024-02-13 | |||
| 2021-09-30 | $120.62M 10-Q · filed 2022-10-25 | |||
| 2021-06-30 | $61.24M 10-Q · filed 2022-07-26 | |||
| 2021-03-31 | $55.11M 10-Q · filed 2022-04-26 | |||
| 2020-12-31 | $145.85M 10-K · filed 2023-02-14 | |||
| 2020-09-30 | $87.31M 10-Q · filed 2021-10-26 | |||
| 2020-06-30 | $28.98M 10-Q · filed 2021-07-27 | |||
| 2020-03-31 | $2.08M 10-Q · filed 2021-04-27 | |||
| 2019-12-31 | $108.64M 10-K · filed 2022-02-15 | |||
| 2019-09-30 | $56.01M 10-Q · filed 2020-10-27 | |||
| 2019-06-30 | -$3.18M 10-Q · filed 2020-07-28 | |||
| 2019-03-31 | $6.84M 10-Q · filed 2020-04-29 | |||
| 2018-12-31 | -$3.21M 10-K · filed 2021-02-16 | |||
| 2018-09-30 | -$4.24M 10-Q · filed 2019-10-29 | |||
| 2018-06-30 | -$4.25M 10-Q · filed 2019-07-30 | |||
| 2018-03-31 | -$4.24M 10-Q · filed 2019-04-30 | |||
| 2017-12-31 | -$10.91M 10-K · filed 2020-02-25 | |||
| 2017-09-30 | -$13.16M 10-Q · filed 2018-10-30 | |||
| 2017-06-30 | -$8.08M 10-Q · filed 2018-07-31 | |||
| 2017-03-31 | -$7.80M 10-Q · filed 2018-05-01 | |||
| 2016-12-31 | $19.67M 10-K · filed 2019-02-26 | |||
| 2016-09-30 | $262.00K 10-Q · filed 2017-10-31 | |||
| 2016-06-30 | -$697.00K 10-Q · filed 2017-08-01 | |||
| 2015-12-31 | -$37.65M 10-K · filed 2018-02-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (CRL) | United States | $14.060B | -43.97 |
| INCYTE CORP (INCY) | United States | $24.855B | 13.14 |
| Absci Corp (ABSI) | United States | $1.775B | -14.92 |
| OmniAb, Inc. (OABI) | United States | $0.698B | -8.05 |
| NRC HEALTH (NRC) | United States | $0.450B | 42.50 |
| MAXCYTE, INC. (MXCT) | United States | $0.124B | -3.68 |
| bioAffinity Technologies, Inc. (BIAF) | United States | $0.063B | |
| OneMedNet Corp (ONMD) | $0.042B | ||
| iSpecimen Inc. (ISPC) | United States | $0.003B | |
| FOXO TECHNOLOGIES INC. (FOXO) | United States | $0.000B | -277.71 |